Understanding Lenalidomide Mutations Mds Outcomes
Exploring Lenalidomide Mutations Mds Outcomes reveals several interesting facts. Valeria Santini, MD, University of Florence, Florence, Italy, discusses the use of
Key Takeaways about Lenalidomide Mutations Mds Outcomes
- Dr. Raza discusses two situations, patients with and without deletion 5q, where the use of
- Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the use of APR-246, a PRIMA-1 analog ...
- David Steensma, MD of the Dana-Faber Cancer Institute, Boston, MA gives an overview of his talk on how to treat patients with ...
- Learn more about
- This video is part of the HMP Education content archive and may include previously accredited educational material. While this ...
Detailed Analysis of Lenalidomide Mutations Mds Outcomes
This video is part of the HMP Education content archive and may include previously accredited educational material. While this ... Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the Valeria Santini, MD from the University of Florence, Florence, Italy discusses the impact of somatic gene
Dr. Goldberg discusses what factors to consider when implementing the oral agent
Stay tuned for more updates related to Lenalidomide Mutations Mds Outcomes.
